BDBM755270 2,2'',2″-(10-(2-((6-((2-((3-((3-((1S,4R,Z)-9-amino-4-((4-hydroxybenzyl)carbamoyl)-1-(isoindolin-2-yl)-2,11,16-trioxo-3,8,10,12,15-pentaazaoctadec-9-en-1-yl)phenyl)amino)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)hexyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid-formic acid (1/1) ::US20250213735, Compound 2

SMILES CCC(=O)NCCNC(=O)/N=C(/N)NCCC[C@@H](NC(=O)[C@H](c1cccc(NCCCNc2c(NCCCCCCNC(=O)CN3CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC3)c(=O)c2=O)c1)N1Cc2ccccc2C1)C(=O)NCc1ccc(O)cc1

InChI Key

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 755270   

TargetNeuropeptide Y receptor type 1(Human)
Radionetics Oncology

US Patent
LigandPNGBDBM755270(2,2',2″-(10-(2-((6-((2-((3-((3-((1S,4R,Z)-9-amino-...)
Affinity DataKi: <10nMAssay Description:TBDMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/23/2025
Entry Details
US Patent